ARKG250509C24000
- 0.03
- +0.01+50.00%
ARK Genomic Revolution ETF Newsroom
Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.
Natera GAAP EPS of -$0.50 Beats by $0.12, Revenue of $501.8M Beats by $55.13M
Trending Industry Today: ARK Genomic Revolution ETF Leads Gains In ARK ETFs Stocks
Tempus AI Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Results and Raised Its FY25 Sales Guidance.
CRISPR Therapeutics Analyst Ratings
Natera To Present Multiple Datasets In Breast Cancer Together With Collaborators At 2025 ESMO Breast Cancer Annual Congress In Munich
Twist Bioscience And Ginkgo Bioworks Announces Revision In Its Three-Year $15M Collaboration Including Ginkgo Receiving Preferential Pricing With No Required Minimum Purchase Volume
Breaking Down Veracyte: 7 Analysts Share Their Views
Needham Maintains Buy on Veracyte, Lowers Price Target to $41
Veracyte Analyst Ratings
Veracyte Projects Strong Decipher and Afirma Growth, Targets 22.5% Adjusted EBITDA Margin for 2025
Cathie Wood Strengthens AI Chip Holdings With Nvidia And AMD Purchases, Reduces Palantir Position By Another $38.8 Million
Schrödinger Projects Strong 2025 Revenue Growth With $45M-$50M in Drug Discovery
Schrodinger Q1 Adj. EPS $(0.64) Beats $(0.75) Estimate, Sales $59.55M Beat $54.65M Estimate
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
Wells Fargo Maintains Overweight on Beam Therapeutics, Lowers Price Target to $70
Preview: Natera's Earnings
Here Are the Major Earnings After the Close Today
10 Analysts Assess Beam Therapeutics: What You Need To Know